The Lymphoma Hub was pleased to speak to Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, what factors influence Bruton’s tyrosine kinase inhibitor (BTKi) + B-cell lymphoma 2 inhibitor (BCL-2i) treatment selection for patients with chronic lymphocytic leukemia (CLL)?

This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak to Charles Herbaux, University of Montpellier, FR. Herbaux discussed the latest updates from the phase III STARGLO trial (NCT04408638), with a focus on second-line (2L) and third-line+ (3L+) data.

This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL).

The symposium concluded with a Q&A session, where the panelists, Gilles Salles, Julie Vose, Wojciech Jurczak, and Michael Wang, answered questions from the live audience.

This educational resource is independently supported by Eli Lilly and Company. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource

Hosted on Acast. See acast.com/privacy for more information.

During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we share a presentation by Michael Wang, MD Anderson Cancer Center, Houston, US, discussing current therapies for MCL and their combinations.

Wang provided an overview of current therapies for MCL, highlighted key clinical data, and offered insights into their clinical application. He also discussed novel therapies and combinations, and potential future directions.

This educational resource is independently supported by Eli Lilly and Company. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. 

Hosted on Acast. See acast.com/privacy for more information.

During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we share a case-based presentation and panel discussion led by Wojciech Jurczak, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, PL, on sequencing therapies and practical management of adverse events in mantle cell lymphoma (MCL). 

This educational resource is independently supported by Eli Lilly and Company. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.  

Hosted on Acast. See acast.com/privacy for more information.

During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). Here, we share a presentation by Julie Vose, University of Nebraska Medical Center, Omaha, US, discussing unmet needs in the treatment of MCL. 

Vose provides an overview of the current treatment landscape for patients with MCL, including Bruton’s tyrosine kinase inhibitors (BTKi), chimeric antigen receptor (CAR) T-cell therapies, and bispecific antibodies. Vose also discusses mechanisms of resistance to BTKi and the impact on patient outcomes.  

This educational resource is independently supported by Eli Lilly and Company. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. 

Hosted on Acast. See acast.com/privacy for more information.

During the Lymphoma Hub Steering Committee meeting, Grzegorz Nowakowski, the Mayo Clinic, Rochester, US, chaired a discussion on anti-CD19 monoclonal antibodies for the treatment of DLBCL.

This discussion also featured Gilles Salles, Sonali Smith, Ulrich Jäger, Catherine Thieblemont, Michael Dickinson, Francesc Bosch, Miles Prince, and Marek Trněný.

Prior to the discussion, Nowakowski presented an overview of tafasitamab (Tafa), a CD19 monoclonal antibody, for the treatment of diffuse large B-cell lymphoma (DLBCL). He highlighted its mechanism of action and discussed the rationale for combining it with lenalidomide (Len) to improve immune-mediated antitumor activity. He reviewed data from the L-MIND trial, where Tafa-Len combination demonstrated a high overall response rate and durable remissions in relapsed/refractory (R/R) DLBCL. He also summarized real-world evidence showing consistent efficacy in patients meeting L-MIND eligibility criteria. Additional insights included the feasibility of using Tafa-Len prior to chimeric antigen receptor (CAR) T-cell therapy, the preservation of CD19 expression post-exposure, and the ongoing FrontMIND trial evaluating Tafa-Len + rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) in previously untreated high-risk DLBCL.

This educational resource is independently supported by Incyte. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

During the Lymphoma Hub Steering Committee Meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on cereblon E3 ligase modulators (CELMoDs) for the treatment of non-Hodgkin lymphoma.

This discussion also featured Grzegorz Nowakowski, Sonali Smith, Ulrich Jäger, Catherine Thieblemont, Michael Dickinson, Francesc Bosch, Miles Prince, and Marek Trněný.

Prior to the discussion, Salles presented an overview of CELMoDs, highlighting their mechanism of action and introducing golcadomide as a novel agent under investigation for lymphomas. He reviewed emerging clinical data from early-phase trials evaluating golcadomide and iberdomide in relapsed/refractory non-Hodgkin lymphoma, including monotherapy and combinations with monoclonal antibodies. Additionally, he outlined the ongoing phase III GOLSEEK-1 and phase II GOLSEEK-2 trials investigating golcadomide in combination with rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) for high-risk large B-cell lymphoma and with rituximab for newly diagnosed advanced-stage follicular lymphoma, respectively.

This educational resource is independently supported by Bristol Myers Squibb. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

During the 18th International Conference on Malignant Lymphoma (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US. We asked, What do the initial results from the LOTIS-7 (NCT04970901) trial suggest for loncastuximab tesirine plus glofitamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?

In this interview, Dr Alderuccio discussed preliminary data presented at the 18-ICML from the LOTIS-7 clinical trial, a multicenter study exploring novel combination therapies in relapsed or refractory B-cell lymphomas. The discussion focused on the combination of loncastuximab tesirine plus glofitamab, highlighting initial findings on safety, efficacy, and potential implications for patients with DLBCL. 

This educational resource is independently supported by Sobi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. 

Hosted on Acast. See acast.com/privacy for more information.

During the 18th International Conference on Malignant Lymphomas (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. We asked about the clinical significance of the long-term results from the EPCORE NHL-2 (NCT04663347) trial, which evaluated epcoritamab (epcor) in combination with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP) in patients with B-cell non-Hodgkin lymphoma. 

During this interview, Dr Joshua Brody discussed the latest data presented at the 18th ICML 2025 from the EPCORE NHL-2 study, with a focus on the cohort of patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with epcor + R-CHOP as frontline therapy. Brody highlighted the significance of durable remission in this difficult-to-treat population, provided an overview of the top-line data from the trial, and discussed upcoming developments, including the phase III randomized EPCORE DLBCL-2 (NCT05578976) trial, which is currently underway and will further evaluate the efficacy and safety of adding epcor to standard R-CHOP in this high-risk patient population.

This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. 

During the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub was pleased to speak to Gareth Gregory, Monash University, Melbourne, AU. We asked about the latest updates from the STARGLO trial of glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) vs rituximab plus gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). 

In this interview, Gregory shares data from the phase III STARGLO trial (NCT04408638) of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL. Gregory covers key outcomes, highlighting 2-year efficacy and safety data. He concludes that the data are encouraging and support using this combination as a fixed-duration, off-the-shelf therapy for patients with R/R DLBCL. 

Hosted on Acast. See acast.com/privacy for more information.

This educational resource is independently supported by AbbVie. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. 

During the 30th European Hematology Association (EHA) Congress, the Lymphoma Hub was pleased to speak to Marek Trněný, Charles University, Prague, CZ. We asked, How effective is epcoritamab + R-ICE in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are eligible for autologous stem cell transplantation (ASCT)? 

In this interview, Trněný shares the first efficacy and safety data from the phase I/II EPCORE NHL-2 trial (NCT04663347) of epcoritamab + R-ICE in patients with R/R DLBCL. Trněný concludes that the encouraging data support the viability of using this combination for patients with R/R DLBCL who are eligible for ASCT. 

Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak to Grzegorz S. Nowakowski, Mayo Clinic, Rochester, US, who discussed the real-world experience of tafasitamab and lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma. 

This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. 

Hosted on Acast. See acast.com/privacy for more information.

This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. 

Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, discusses the evolving treatment landscape for relapsed/refractory diffuse large B-cell lymphoma, focusing on the combination of tafasitamab and lenalidomide. He highlights how this immunotherapy regimen, targeting CD19, has shown promising efficacy, with a high overall response rate and sustained complete responses in some patients. Salles also addresses real-world data, the regimen’s tolerability, and its positioning in the treatment sequence, particularly for patients who are not candidates for CAR T-cell therapy. Lastly, he emphasizes the importance of tailoring treatment strategies based on patient characteristics and emerging therapies. 

Hosted on Acast. See acast.com/privacy for more information.

During the 66th American Society of Hematology (ASH) Meeting and Exposition, the Lymphoma Hub was pleased to speak to Stefano Luminari, University of Modena and Reggio Emilia, Modena, IT. We asked about the latest updates from the inMIND trial of tafasitamab plus lenalidomide and rituximab for R/R FL.

In this interview, Luminari shares data from the phase III inMIND (NCT04680052) trial of patients with relapsed/refractory follicular lymphoma treated with tafasitamab in combination with lenalidomide and rituximab. Luminari covers key outcomes, highlighting promising efficacy and safety data. He concludes that the data are encouraging and supports using this combination for patients with relapsed/refractory follicular lymphoma in the second-line setting.

This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked about the latest updates from the SEQUOIA trial of zanubrutinib + venetoclax in treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 

In this interview, Paolo Ghia shares data from Arm D of the phase III SEQUOIA (NCT03336333) study of patients with del(17p) and/or pathogenic TP53 mutation treated with zanubrutinib in combination with venetoclax. Ghia covers key preliminary outcomes, highlighting promising remission data and an increased depth of response measured over time. This interview concludes with a look at the future implications of these data, particularly on measurable residual disease-guided treatment cessation.

This educational resource is independently supported by BeiGene. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource. 

Hosted on Acast. See acast.com/privacy for more information.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked for an update on the SYMPHONY 1 trial (NCT04224493).

First, Salles explains the rationale for using tazemetostat, an oral EZH2 inhibitor, with lenalidomide and rituximab in the phase Ib SYMPHONY 1 trial for patients with relapsed/refractory follicular lymphoma. This is followed by an overview of the study design and a review of the adverse effects and response rates. The results of this study have prompted the combination to be further investigated in a phase III trial. 

Hosted on Acast. See acast.com/privacy for more information.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Chan Cheah, University of Western Australia, Perth, AU. We asked for an update on novel therapies in chronic lymphocytic leukemia (CLL).

Cheah reviews the abstracts that were presented at ASH on novel BTK inhibitors and Bcl-2 inhibitors for relapsed/refractory CLL. This includes an analysis of the potency, toxicity, and MRD response rates of the Bcl-2 inhibitor, BGB-11417, as well as the results of the phase I/II BRUIN study of the non-covalent BTK inhibitor, pirtobrutinib, in heavily pretreated patients with CLL and patients with Richter’s transformation.

Hosted on Acast. See acast.com/privacy for more information.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Pere Barba, Hospital Universitari Vall d'Hebron, Barcelona, ES. We asked, What are the chimeric antigen receptor (CAR) T-cell therapies on the horizon for lymphoma?

Barba summarizes the progress made in the development of second generation CD19 CAR T-cell therapies, dual CAR T-cell therapies, allogeneic CAR T-cell platforms, alternatives to CD19 CAR T-cell therapies, and combining checkpoint inhibitors with conventional CAR T-cell therapies. 

Hosted on Acast. See acast.com/privacy for more information.